HK1153502A1 - Anti-bst2 antibody bst2 - Google Patents

Anti-bst2 antibody bst2

Info

Publication number
HK1153502A1
HK1153502A1 HK11107441.7A HK11107441A HK1153502A1 HK 1153502 A1 HK1153502 A1 HK 1153502A1 HK 11107441 A HK11107441 A HK 11107441A HK 1153502 A1 HK1153502 A1 HK 1153502A1
Authority
HK
Hong Kong
Prior art keywords
bst2
antibody
bst2 antibody
antibody bst2
Prior art date
Application number
HK11107441.7A
Other languages
English (en)
Chinese (zh)
Inventor
鴨川由美子
並木佐穗理
趙民權
石田晃司
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Publication of HK1153502A1 publication Critical patent/HK1153502A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK11107441.7A 2007-10-16 2011-07-18 Anti-bst2 antibody bst2 HK1153502A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007269470 2007-10-16
PCT/JP2008/068794 WO2009051201A1 (fr) 2007-10-16 2008-10-16 Anticorps anti-bst2

Publications (1)

Publication Number Publication Date
HK1153502A1 true HK1153502A1 (en) 2012-03-30

Family

ID=40567462

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11107441.7A HK1153502A1 (en) 2007-10-16 2011-07-18 Anti-bst2 antibody bst2

Country Status (15)

Country Link
US (2) US8529896B2 (fr)
EP (1) EP2210939A4 (fr)
JP (1) JP5558825B2 (fr)
KR (1) KR20100090258A (fr)
CN (2) CN104031150A (fr)
AU (1) AU2008312858A1 (fr)
BR (1) BRPI0817427A8 (fr)
CA (1) CA2702939A1 (fr)
HK (1) HK1153502A1 (fr)
IL (1) IL205073A (fr)
MX (1) MX2010004251A (fr)
NZ (1) NZ585394A (fr)
RU (1) RU2010119450A (fr)
UA (1) UA105760C2 (fr)
WO (1) WO2009051201A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011056561A1 (fr) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Procédés et compositions pour la génération et l'utilisation d'anticorps spécifiques à une conformation
WO2012125724A1 (fr) 2011-03-14 2012-09-20 Beth Israel Deaconess Medical Center Méthodes et compositions pour le traitement de troubles prolifératifs
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
US9439884B2 (en) 2011-05-26 2016-09-13 Beth Israel Deaconess Medical Center, Inc. Methods for the treatment of immune disorders
CA2875798A1 (fr) 2012-06-07 2013-12-12 Beth Israel Deaconess Medical Center, Inc. Procedes et compositions pour inhiber pin1
WO2014066271A1 (fr) * 2012-10-22 2014-05-01 Becton, Dickinson And Company Cellules de lignage non b capables de produire des anticorps
WO2014152157A2 (fr) * 2013-03-15 2014-09-25 Bethisrael Deaconess Medical Center, Inc. Procédés et compositions pour la génération et l'utilisation d'anticorps spécifiques à une conformation
US9968579B2 (en) 2014-07-17 2018-05-15 Beth Isreal Deaconess Medical Center, Inc. ATRA for modulating Pin1 activity and stability
WO2016011265A2 (fr) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarqueurs pour troubles associés à pin1
SG11201700496WA (en) 2014-07-22 2017-02-27 Cb Therapeutics Inc Anti-pd-1 antibodies
US10435470B2 (en) * 2014-08-05 2019-10-08 Cb Therapeutics, Inc. Anti-PD-L1 antibodies
WO2016145186A1 (fr) 2015-03-12 2016-09-15 Beth Israel Deaconess Medical Center, Inc. Composés apparentés à atra améliorés pour le traitement de maladies prolifératives, de maladies auto-immunes et d'affections addictives
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
US20230235074A1 (en) * 2020-06-19 2023-07-27 Board Of Regents, The University Of Texas System Anti-bst2 antibodies targeting bst2 long isoform

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US305121A (en) * 1884-09-16 Razor-strop
ZA948016B (en) * 1993-10-15 1995-05-31 Toshio Hirano A membrane protein polypeptide having pre-B cell crowth-supporting ability and a gene thereof
TR199901949T2 (xx) 1997-02-12 2000-01-21 Chugai Seiyaku Kabushiki Kaisha. Lemfositik t�m�rler i�in �areler.
WO1999043803A1 (fr) 1998-02-25 1999-09-02 Chugai Seiyaku Kabushiki Kaisha Gene codant pour la proteine antigenique hm1.24 et son promoteur
EP1354896B1 (fr) 2000-12-28 2010-02-10 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal dirigé contre l'antigène humain bst2
US7931897B2 (en) * 2001-02-07 2011-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for hematopoietic tumors
WO2002084290A1 (fr) * 2001-04-13 2002-10-24 Chugai Seiyaku Kabushiki Kaisha Procede permettant de quantifier l'expression d'antigenes
JP4794303B2 (ja) * 2003-10-10 2011-10-19 中外製薬株式会社 固形腫瘍治療剤
US8435530B2 (en) * 2004-06-11 2013-05-07 Sbi Biotech Co., Ltd. Methods for suppressing activity of activated interferon-producing cells
WO2006013923A1 (fr) * 2004-08-05 2006-02-09 Ginkgo Biomedical Research Institute Co., Ltd. Remède pour l'arthrite accompagnée de maladie autoimmune
JPWO2006054748A1 (ja) 2004-11-22 2008-06-05 Ｓｂｉバイオテック株式会社 腎炎の治療剤
US20080299128A1 (en) 2006-06-20 2008-12-04 Myung Kim Effect of Bst2 on inflammation

Also Published As

Publication number Publication date
JPWO2009051201A1 (ja) 2011-03-03
EP2210939A4 (fr) 2012-08-08
US8529896B2 (en) 2013-09-10
IL205073A (en) 2014-07-31
CN101952426A (zh) 2011-01-19
US20100278832A1 (en) 2010-11-04
CA2702939A1 (fr) 2009-04-23
UA105760C2 (uk) 2014-06-25
KR20100090258A (ko) 2010-08-13
IL205073A0 (en) 2010-11-30
BRPI0817427A2 (pt) 2015-06-16
NZ585394A (en) 2012-05-25
WO2009051201A1 (fr) 2009-04-23
MX2010004251A (es) 2010-08-30
RU2010119450A (ru) 2011-11-27
CN101952426B (zh) 2014-04-16
US20130336967A1 (en) 2013-12-19
CN104031150A (zh) 2014-09-10
JP5558825B2 (ja) 2014-07-23
BRPI0817427A8 (pt) 2019-01-29
AU2008312858A1 (en) 2009-04-23
EP2210939A1 (fr) 2010-07-28

Similar Documents

Publication Publication Date Title
HK1214947A1 (zh) 抗體製劑
GB0708002D0 (en) Antibodies
HK1136970A1 (en) Penta-specific antibody
EP2138576A4 (fr) Anticorps anti-claudine-4
HK1153502A1 (en) Anti-bst2 antibody bst2
HK1146728A1 (en) Modified antibody constant region
IL202648A0 (en) Antibody formulations
HK1207652A1 (en) Antibody formulations
SI2200700T1 (sl) Nova protitelesa
EP2077859A4 (fr) Formulation d'anticorps
EP2172483A4 (fr) ANTICORPS ANTI-Muc17
EP2173163A4 (fr) Formulations d'anticorps
EP2076614A4 (fr) Anticorps synthetiques
HK1133018A1 (en) Anti-myostatin antibodies
GB0615662D0 (en) Antibody
PL2011869T3 (pl) Nowe przeciwciało anty-CD98
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
GB0718737D0 (en) Antibodies
GB0702888D0 (en) Novel Antibodies
EP2015785A4 (fr) Antigène agrm2
EP2167635A4 (fr) Formulations d'anticorps
GB0724185D0 (en) Antibodies
GB0606276D0 (en) Antibodies
GB0607376D0 (en) Antibodies
GB0723044D0 (en) Lyophillised antigen composition

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171016